Frontiers in endocrinology · 2025
Machine learning-optimized metabolic biomarker panel for precision screening of early-stage pancreatic cancer in new-onset diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Weiliang, Cheng Zhiyuan, Mu Rong, Sun Haoran, Guo Zihao, Yu Guo, Wang Dongyan, Yang Lijuan
Аннотация
INTRODUCTION: New-onset diabetes (NOD) represents a high-risk population for pancreatic ductal adenocarcinoma (PDAC), yet effective early detection tools for this specific subgroup remain an unmet clinical need.
METHODS: We conducted a prospective serum metabolomic analysis using UHPLC-MS/MS in 133 NOD patients aged >65 years, including 60 with PDAC (PDAC+NOD) and 73 without (NOD). Multivariate analysis (OPLS-DA) and machine learning approaches were employed to identify and optimize a diagnostic metabolic biomarker panel. Model performance was evaluated using a hold-out validation set following TRIPOD-ML guidelines.
RESULTS: We identified 62 differentially expressed serum metabolites (P<0.05, FDR-corrected), primarily implicating branched-chain amino acid metabolism, bile acid biosynthesis, and sphingolipid signaling pathways. Notably, significant reductions in one-carbon metabolism-related metabolites (serine, glycine, homocysteine) were observed in PDAC+NOD patients. Feature selection yielded an optimized 5-metabolite panel comprising glycine, L-serine, L-methionine, L-homocysteine, and L-homocystine. This panel demonstrated high diagnostic accuracy with an AUC of 0.853 (95% CI: 0.786-0.920) and 75.0% accuracy in distinguishing PDAC+NOD from NOD patients.
DISCUSSION: Our study establishes a foundational metabolic biomarker strategy for precision screening of early-stage PDAC in NOD populations. The dysregulated one-carbon metabolites provide novel mechanistic insights into PDAC pathogenesis and offer actionable targets for clinical assay development. Future validation in multi-center cohorts is warranted to confirm clinical utility.
METHODS: We conducted a prospective serum metabolomic analysis using UHPLC-MS/MS in 133 NOD patients aged >65 years, including 60 with PDAC (PDAC+NOD) and 73 without (NOD). Multivariate analysis (OPLS-DA) and machine learning approaches were employed to identify and optimize a diagnostic metabolic biomarker panel. Model performance was evaluated using a hold-out validation set following TRIPOD-ML guidelines.
RESULTS: We identified 62 differentially expressed serum metabolites (P<0.05, FDR-corrected), primarily implicating branched-chain amino acid metabolism, bile acid biosynthesis, and sphingolipid signaling pathways. Notably, significant reductions in one-carbon metabolism-related metabolites (serine, glycine, homocysteine) were observed in PDAC+NOD patients. Feature selection yielded an optimized 5-metabolite panel comprising glycine, L-serine, L-methionine, L-homocysteine, and L-homocystine. This panel demonstrated high diagnostic accuracy with an AUC of 0.853 (95% CI: 0.786-0.920) and 75.0% accuracy in distinguishing PDAC+NOD from NOD patients.
DISCUSSION: Our study establishes a foundational metabolic biomarker strategy for precision screening of early-stage PDAC in NOD populations. The dysregulated one-carbon metabolites provide novel mechanistic insights into PDAC pathogenesis and offer actionable targets for clinical assay development. Future validation in multi-center cohorts is warranted to confirm clinical utility.